Cargando…

Fluvoxamine, melatonin and COVID-19

Detalles Bibliográficos
Autor principal:	Anderson, George M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779245/ https://www.ncbi.nlm.nih.gov/pubmed/33392622 http://dx.doi.org/10.1007/s00213-020-05753-z

Ejemplares similares

Heme oxygenase agonists—fluvoxamine, melatonin—are efficacious therapy for Covid-19
por: Hooper, Philip L.
Publicado: (2021)

Old drug fluvoxamine, new hope for COVID-19
por: Hashimoto, Yaeko, et al.
Publicado: (2021)

Repurposing fluvoxamine, and other psychiatric medications, for COVID‐19 and other conditions
por: Lenze, Eric J., et al.
Publicado: (2022)

Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: A systematic review and meta-analysis
por: Cheema, Huzaifa Ahmad, et al.
Publicado: (2022)

Emergence of kleptomania during treatment for obsessive compulsive disorder with fluvoxamine
por: Gupta, Parveen Rani
Publicado: (2014)

A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference
por: Marcec, Robert, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Psychosis: glia, immunity, and melatonin
por: Anderson, George
Publicado: (2017)

Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Kim, Hyun, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Marzolini, Catia, et al.
Publicado: (2022)

Fluvoxamine Plays an Integral Role in the Alteration of Sexual Behavioral Pattern more in Females than Males
por: Santra, Ranjita
Publicado: (2012)

Delirium, sleep, COVID-19 and melatonin
por: Wiwanitkit, Viroj
Publicado: (2020)

There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
por: Trkulja, Vladimir
Publicado: (2022)

Melatonin and cocaine: role of mitochondria, immunity, and gut microbiome
por: Anderson, George
Publicado: (2020)

Comment on: “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence”
por: Mazza, Mario Gennaro, et al.
Publicado: (2022)

Fluvoxamine for symptomatic outpatients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2022)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”
por: Lenze, Eric J., et al.
Publicado: (2022)

Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Is melatonin deficiency a unifying pathomechanism of high risk patients with COVID-19?
por: Simko, Fedor, et al.
Publicado: (2020)

Rapid effect of suvorexant and high-dose melatonin on COVID-19 associated delirium
por: Nazeer, Sahana, et al.
Publicado: (2023)

Overview of the potential use of fluvoxamine for COVID-19 and long COVID
por: Hashimoto, Kenji
Publicado: (2023)

Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism
por: Papadopoulos, Konstantinos, et al.
Publicado: (2023)

Could Fluvoxamine Dose De-escalation Increase Treatment Compliance Without Sacrificing Efficacy in COVID-19 Patients?
por: Marcec, Robert, et al.
Publicado: (2022)

Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19
por: Mahdi, Mohamed, et al.
Publicado: (2022)

Fluvoxamine for outpatients with COVID-19: where do we stand?
por: Berwanger, Otavio
Publicado: (2022)

Mechanisms of action of fluvoxamine for COVID-19: a historical review
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Seo, Hyeonji, et al.
Publicado: (2022)

Melatonin: Revisited Role as Vaccine Adjuvant During Outbreaks of COVID-19 Caused by the Delta Variant
por: Kow, Chia Siang, et al.
Publicado: (2021)

Fluvoxamine in the treatment of anxiety disorders
por: Irons, Jane
Publicado: (2005)

Melatonin’s actions are not limited to sleep
por: Venaki, Evangelia, et al.
Publicado: (2023)

Why we should not recommend or offer fluvoxamine to COVID-19 patients?
por: Trkulja, Vladimir
Publicado: (2022)

Effectiveness of fluvoxamine at preventing COVID-19 infection from turning severe
por: Boretti, Alberto
Publicado: (2023)

Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
por: Sukhatme, Vikas P., et al.
Publicado: (2021)

MELATONIN/CORTISOL RATIO IN PSYCHIATRIC ILLNESS
por: Ferrier, I.N, et al.
Publicado: (1982)

Melatonin as fetal neuroprotection: Links and risks
por: Ghotbizadeh Vahdani, Fahimeh, et al.
Publicado: (2020)

Fluvoxamine pour les patients atteints de COVID-19 non hospitalisés
por: Wu, Peter E., et al.
Publicado: (2022)

Melatonin: Miracles far beyond the pineal gland
por: Afzal, Rafia
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9feejnpe63s8q7n1m7a1ttjfev